Charité - Universitätsmedizin Berlin

Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence (2022) Merola E, Pascher A, Rinke A, Bartsch DK, Zerbi A, Nappo G, Carnaghi C, et al. Journal article Aligning Biobanks and Data Integration Centers Efficiently (ABIDE_MI) (2022) Prokosch HU, Baber R, Bollmann P, Gebhardt M, Gründner J, Hummel M Book chapter / Article in edited volumes Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab (2022) Gerdes S, Asadullah K, Hoffmann M, Korge B, Mortazawi D, Wegner S, Personke Y, et al. Journal article Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention (2022) Rai H, Harzer F, Otsuka T, Abdelwahed YS, Antuna P, Blachutzik F, Koppara T, et al. Journal article Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT (2022) Machowicz R, Suarez F, Wiktor-Jedrzejczak W, Eikema DJ, De Wreede LC, Blok HJ, Isaksson C, et al. Journal article Extracorporeal Membrane Oxygenation Blood Flow and Blood Recirculation Compromise Thermodilution-Based Measurements of Cardiac Output (2022) Russ M, Steiner E, Boemke W, Busch T, Melzer-Gartzke C, Taher M, Badulak J, et al. Journal article Multiple motion encoding in phase-contrast MRI: A general theory and application to elastography imaging (2022) Herthum H, Carrillo H, Osses A, Uribe S, Sack I, Bertoglio C Journal article A POLYGENIC RISK SCORE FOR REDUCED EGFR IS ASSOCIATED WITH ADVERSE EVENTS IN A CHRONIC KIDNEY DISEASE COHORT - THE GERMAN CHRONIC KIDNEY DISEASE STUDY (2022) Steinbrenner I, Yu Z, Jin J, Schultheiss UT, Kotsis FK, Grams M, Coresh J, et al. Conference contribution Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B (2022) Furlanetto J, Marme F, Thode C, Nekljudova V, Liu Y, Jimenez MM, Reimer T, et al. Conference contribution Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution